We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. 82.8% of patients treated with Vtama achieved the ...
Among patients with psoriasis affecting special anatomical sites, IL-17 inhibitors are associated with significant improvements in PASI 75 and 90.
Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics, discusses the need for increased research and awareness on intertriginous disease in psoriasis. I think a survey like ...
Intertriginous plaque psoriasis, also known as inverse psoriasis, affects approximately 20%–30% of individuals who have plaque psoriasis. The treatment for plaque psoriasis in intertriginous areas is ...
Please provide your email address to receive an email when new articles are posted on . Psoriasis on the scalp, face, palmoplantar areas, nails, intertriginous area and genitalia is often hard to ...
LONG BEACH, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in ...
Credit: Arcutis Biotherapeutics. The approval was based on data from the two phase 3 trials that included patients aged 12 years and older with mild to severe plaque psoriasis. The Food and Drug ...
Two posters presented at the 2023 Fall Clinical Dermatology Conference examined patient demographics, clinical characteristics, and outcomes in patients with plaque psoriasis treated with tapinarof ...
The woman had axillary granular parakeratosis (GP), a benign condition. First described in 1991, this disease presents with erythematous hyperpigmented and hyperkeratotic papules and plaques in ...
Systemic oral phosphodiesterase type 4 (PDE-4) inhibitors have been effective in the treatment of psoriasis. Roflumilast cream contains a PDE-4 inhibitor that is being investigated for the topical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results